Cardiometabolic Disorders News

Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported.

Adults diagnosed with COVID-19 who had long COVID at a 6-month follow-up had lower vitamin D levels than COVID-19 survivors without long COVID, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Leading experts from cardiorenal metabolic specialties will present the latest research with clinical implications for diabetes, CVD and kidney disease, with a new format this year designed to drive multispecialty discussions.

Among Medicaid beneficiaries with diabetes and heart failure in Alabama, many did not have a follow-up visit within 14 days of hospitalization in accordance with guidelines, researchers reported.

Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.

In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”

Adults with obesity who used semaglutide for weight loss reduced their 10-year risk for atherosclerotic cardiovascular disease, according to findings presented at the European Congress on Obesity.

Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity.

Among patients hospitalized for acute MI, those with diabetes had greater risk for death than those without it, according to data from the Atherosclerosis Risk in Communities cohort.

The FDA is advising people using semaglutide to avoid some compounded formulations due to the use of ingredients that may cause adverse events, according to a safety notice.